# A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

> **NCT03583606** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 61 (actual)

## Conditions studied

- Ebola Disease
- Immunisation

## Interventions

- **BIOLOGICAL:** ChAd3-EBO-Z
- **BIOLOGICAL:** MVA Multi-Filo Ebola Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03583606
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2020-01-14
- **Final completion:** 2020-01-14
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583606, "A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03583606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*